Characteristics and long-term outcomes of patients with rheumatoid arthritis and concurrent calcium pyrophosphate deposition disease

Rheumatoid Arthritis

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Semin Arthritis Rheum

Raskin N, Hiligsmann M, Rebutoc AR, Bansback N, Boonen A, Buchbinder R, Falahee M, Fraenkel L, Marshall DA, Maxwell L, Nieuwlaat R, Proulx L, Saadat P, Shea B, Tugwell P, Wiercioch W, Beaton D, Richards P, Schünemann H, Guillemin F, Hazlewood GS

doi: 10.1016/j.semarthrit.2025.152769

Rheumatoid Arthritis

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Lancet Rheumatol

Cope AP, Jasenecova M, Vasconcelos JC, Qureshi S, van Schie KA, Filer A, Raza K, D'Agostino MA, McInnes IB, Siebert S, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Mankia K, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga TWJ, Toes REM, Georgiou E, Kelly J, Murphy C, Prevost AT, ALTO Study Investigators

doi: 10.1016/S2665-9913(25)00371-6

Rheumatoid Arthritis

Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Rasch measurement theory to identify items and domains

Rheumatology (Oxford)

Pickles T, Horton M, Christensen KB, Phillips R, Gillespie D, Mo N, Davies J, Campbell S, Choy E

doi: 10.1093/rheumatology/keaf189

Rheumatoid Arthritis

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Arthritis Care Res (Hoboken)

Xie F, Beukelman T, McCormick NP, Curtis JR

doi: 10.1002/acr.80010

Rheumatoid Arthritis

Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicenter cohort of 526 patients

Rheumatology (Oxford)

Serrano-Combarro A, Atienza-Mateo B, Martín-Gutierrez A, Ibarrola Paino L, Casafont-Solé I, Loarce-Martos J, Blanco-Madrigal JM, Ortega-Castro R, Mena-Vázquez N, Fernández-Díaz C, Loricera J, Ferrer D, Castañeda S, Blanco R, Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis

doi: 10.1093/rheumatology/keag023

Further Publications Rheumatology

Difficult to manage axial spondyloarthritis patients have high burden of pain-related comorbidities and adverse long-term outcome

Arthritis Res Ther

Bertsias A, Flouri I, Emmanouilidou E, Repa A, Avgoustidis N, Kalogiannaki E, Pitsigavdaki S, Bertsias G, Sidiropoulos P

doi: 10.1186/s13075-026-03732-x

Psoriatic Arthritis

Clinical Significance of Gut Microbiota Community Types for Long-term Response to Fecal Microbiota Transplantation in Patients with Psoriatic Arthritis

Arthritis Rheumatol

Qin P, Kragsnaes MS, Holm DK, Horn HC, Nilsson AC, Kjeldsen J, Kristiansen K, Ellingsen T

doi: 10.1002/art.43359

Rheumatoid Arthritis

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex

Arthritis Res Ther

Flouri ID, Repa A, Avgoustidis N, Pitsigavdaki S, Kalogiannaki E, Kalligianni-Sofikiti K, Emmanouilidou E, Marolachaki E, Bertsias G, Sidiropoulos P

doi: 10.1186/s13075-025-03664-y

Rheumatoid Arthritis

Disease activity predicts the development of cardiovascular events in patients with rheumatoid arthritis from the CARMA cohort

Semin Arthritis Rheum

Llorca J, Ferraz-Amaro I, Castañeda S, Plaza Z, Sánchez-Alonso F, García-Gómez C, González-Juanatey C, González-Gay MÁ, CARMA Project Collaborative Group

doi: 10.1016/j.semarthrit.2025.152833

Related content

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Rasch measurement theory to identify items and domains

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicenter cohort of 526 patients

Difficult to manage axial spondyloarthritis patients have high burden of pain-related comorbidities and adverse long-term outcome

Clinical Significance of Gut Microbiota Community Types for Long-term Response to Fecal Microbiota Transplantation in Patients with Psoriatic Arthritis

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex

Disease activity predicts the development of cardiovascular events in patients with rheumatoid arthritis from the CARMA cohort